Immortalization (senescence bypass) is a critical rate-limiting step in the malignant transformation of mammalian somatic cells. Human cells must breach at least two distinct senescence barriers to permit unfettered clonal evolution during cancer development: (1) stress-or oncogene-induced premature senescence (SIPS/OIS), mediated via the p16 --Rb and/or ARF --p53 --p21 tumour-suppressive pathways, and (2) replicative senescence triggered by telomere shortening. In contrast, because their telomerase is constitutively active, cells from small rodents possess only the SIPS/OIS barrier, and are therefore useful for studying SIPS/OIS bypass in isolation. Dermal fibroblasts from the Syrian hamster (SHD cells) are exceptionally resistant to spontaneous SIPS bypass, but it can be readily induced following exposure to a wide range of chemical and physical carcinogens. Here we show that a spectrum of carcinogen-specific mutational and epigenetic alterations involving the INK4A (p16), p53 and INK4B (p15) genes are associated with induced SIPS bypass. With ionizing radiation, immortalization is invariably accompanied by efficient biallelic deletion of the complete INK4/CDKN2 locus. In comparison, SHD cells immortalized by the powerful polycyclic hydrocarbon carcinogen benzo(a)pyrene display transversion point mutations in the DNA-binding domain of p53 coupled with INK4 alterations such as loss of expression of p15. Epimutational silencing of p16 is the primary event associated with immortalization by nickel, a human non-genotoxic carcinogen. As SIPS/OIS bypass is a prerequisite for the immortalization of normal diploid human epithelial cells, our results with the SHD model will provide a basis for delineating combinations of key molecular changes underpinning this important event in human carcinogenesis.
INTRODUCTION
The development of cancer is a multi-step process driven by clonal evolution. Clonal evolution requires that the evolving neoplastic lineage has an infinite capacity for self-renewal (cellular immortality), and this is dependent on bypass of powerful cellular senescence barriers that act as critical tumour-suppressive safeguards (reviewed in Newbold 1 ). Recently, it has become clear that there exists more than one kind of cellular senescence barrier. 2 In human somatic cells (and those of other large mammals), the telomere maintenance enzyme---the ribonucleoprotein telomerase---is switched off in most of the soma at some point after 20 weeks of development via transcriptional silencing of the gene encoding its catalytic subunit, human telomerase reverse transcriptase. This results in telomere attrition and eventual telomere uncapping, triggering the p53-mediated DNA-damage response. The DNA-damage response recognizes one or more uncapped telomeres as double-strand DNA breaks and precipitates an irreversible state of growth arrest known as replicative senescence.
1,2 Somatic cells from small rodents (for example, mouse, hamster, rat), in marked contrast, retain telomerase activity but still undergo senescence in culture after a predictable number of population doublings. 1, 3, 4 This telomere-independent senescence process is now believed to be the result of stress, in vitro (for example, the supra-physiological levels of oxygen and inappropriate extracellular matrix encountered in standard tissue culture conditions) 5 or indeed in vivo (for example, during ageing, or possibly in cells removed from their normal tissue niche in the very early stages of carcinogenesis), 2 and is therefore termed 'stress-induced premature senescence' (SIPS). SIPS is mediated by the p16 --Rb and/or ARF --p53 --p21 antiproliferative pathways, which are also functionally damaged in the vast majority of human malignancies. A parallel senescence process, known as oncogene-induced senescence (OIS), 6 which is mechanistically similar to SIPS, is observed when normal diploid cells encounter activated oncogenes (for example, ras, raf). Replicative senescence, SIPS, and OIS are all believed to act as critical tumour-suppressive barriers to cell immortalization and therefore malignant transformation. 6, 7 Human somatic cells possess both replicative senescence and SIPS/OIS (possibly a dual protection against clonal evolution and cancer), whereas small, short-lived rodents rely solely on the latter senescence mechanism. 1, 4 Because the immortalization of normal rodent cells does not require telomerase activation, molecular mechanisms underpinning bypass of SIPS/OIS can be studied in isolation. Syrian hamster somatic cells, for example primary dermal fibroblasts (Syrian hamster dermal (SHD)) or mixed embryonic cultures (Syrian hamster embryo (SHE)) are particularly useful in this regard because: (1) they exhibit an extremely low propensity for spontaneous SIPS/OIS bypass and immortalization (o10 À9 /cell passaged), (2) they possess telomerase activity throughout their culture lifespan (even when terminally senescent) 3 and (3) they are responsive to SIPS/OIS bypass induction by a variety of human carcinogens. 8 We previously used both SHD and SHE cells to demonstrate for the first time that induction of cellular immortality is an early and essential event in malignant transformation effected by powerful chemical and physical carcinogens 9 and also by activated oncogenes. 10 Furthermore, in the latter study (using the cloned human oncogene EJ-Ha-ras) we described, at the cellular level, the phenomenon of OIS, the mechanism for which (namely, the relative roles of p16, ARF and p53), and its significance in tumour suppression, was unravelled subsequently 6 in mouse and human cells. In large part, because of their low susceptibility to spontaneous immortalization, primary cells from the Syrian hamster have proved popular for use in in vitro cell transformation assays for detecting carcinogens.
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In the present study we sought to characterize the mechanisms underlying SIPS/OIS bypass in normal diploid SHD cells, deploying a group of functionally diverse chemical (benzo(a)pyrene, N-methyl-N-nitrosourea (MNUA), dimethylsulphate (DMS) and nickel ions) and physical (low-and high-linear energy transfer (LET) ionizing radiation (IR)) carcinogens to induce the immortal phenotype. For a summary of the main types of alteration induced by each of these carcinogens in mammalian cells, see Table 1 , Newbold et al.
12 --14 and Arita and Costa. 15 Such an approach permitted the induction, genome-wide, of a broad spectrum of genetic and epigenetic alterations, allowing us to define more precisely the diversity of possible changes within critical antiproliferative pathways that can combine to overcome SIPS/ OIS. Our results show that different human carcinogens display a distinct preference for inactivating different elements of the p16 --Rb and ARF --p53 --p21 senescence effector pathways. We show that biallelic deletion of the complete INK4A/B (CDKN2A/B) locus, incorporating the p16, ARF and p15 tumour suppressors, is invariably the cause of immortalization induced (in a single step 9, 10 ) by both low-and high-LET IR. A surprisingly efficient potency for IR was revealed in this respect. Furthermore, we pinpoint a possible role for epigenetic p15 silencing acting cooperatively in a two-stage process, 8, 9 with a single carcinogeninduced point mutation in p53 to accomplish senescence bypass induced by the powerful human carcinogen benzo(a)pyrene (B(a)P) and its ultimate reactive diol epoxide metabolite (BPDE). Finally, we identify epigenetic silencing of p16 as the critical event underpinning senescence bypass induced by the human nongenotoxic carcinogen, nickel.
RESULTS
Induction of senescence bypass in normal SHD cells by different classes of human carcinogen Carcinogens (Table 1) were used to immortalize mass cultures of tertiary SHD cells. 8, 9 The numbers of target cells/dish and the dose of carcinogen were chosen such that an overall average of less than one immortalization event would be expected to occur per dish in order to maximize the probability of true clonality. All clones that had bypassed senescence were confirmed as immortal by the criterion that they were able to proliferate for at least 50 population doublings following their emergence as a mass culture. For further details of immortalization frequencies, criteria and induction kinetics in the SHD system, see Trott et al. 8 and Newbold et al. 9 Molecular analysis was performed on 25 SHD cell clones induced by IR (low-LET X-rays and high-LET fast neutrons; 7 clones analyzed), three powerful point mutagenic chemical carcinogens (benzo(a)pyrene, its reactive anti-diol epoxide metabolite and N-methyl-N-nitrosourea; 13 clones), a weakly point mutagenic but clastogenic DNA methylating carcinogen (DMS; 1 clone) and a non-genotoxic (epigenetic) human carcinogen (divalent nickel ions; 4 clones).
Homozygous CDKN2A/B (p16, ARF and p15) gene deletion accounts for radiation-and DMS-induced senescence bypass in SHD cells The CDKN2A/B (INK4A/B) locus encodes three important tumoursuppressor genes, p16 (INK4A), ARF and p15 (INK4B), that are strongly implicated in cellular senescence. 16 Along with p53, p16 is one of the most commonly altered genes in human cancer, with biallelic losses and promoter hypermethylation being the most common silencing events. 16, 17 Relative expression of mRNAs encoded by p16, ARF and p15 were analysed by quantitative reverse transcriptase-PCR (qPCR) in all IR-induced and DMSinduced clones (Figures 1a --c) . The mRNA expression levels were normalized to the endogenous housekeeping gene GAPDH. In the case of seven IR-induced lines and the single DMS-induced immortal variant line, the expression of both p16 and ARF mRNAs was completely extinguished, suggesting that the INK4A locus may have been consistently deleted in immortal clones induced Benzo(a)pyrene is activated by P450 enzymes to diol epoxide metabolites (anti-and syn-B(a)P-7,8 dihydrodiol-9,10-oxides). The major DNA adduct, the (+)-anti-B(a)P-N2 guanine adduct (B(a)P-anti-diol epoxide), promotes mispairing (with adenine) leading mainly to G to T transversion mutations. The anti-B(a)P-diol epoxide displays exceptional mutagenic potency in mammalian cells. 13 Carcinogen-specific events driving senescence bypass H Yasaei et al by exposure to these agents (Figures 1a and b) . We therefore analyzed expression of the closely linked gene p15 (colocalized within CDKN2A/B in humans and rodents). No expression of p15 mRNA was detectable in any of the seven IR-induced lines or the DMS-immortalized clone ( Figure 1c ). To confirm the physical loss of all INK4A/B (CDKN2A/B) alleles, we analyzed copy number variations (CNVs) in purified DNA samples using a commercially designed (Applied Biosystems, Life Technologies, Carlsbad, CA, USA) TaqMan copy number assay based on the available Syrian hamster p16, ARF and p15 sequences in the NCBI (National Centre for Biotechnology Information) database (ncbi.nlm.nih.gov). As expected, absence of a PCR product indicated the presence of a homozygous CDKN2A/B deletion in all seven IR-induced and the single DMS-induced immortal clones (Table 2 ). Complete physical loss of INK4A was further confirmed by Southern analysis of DNAs employing hamster p16 complementary DNA (cDNA) as a probe (data not shown). Thus, the size of the homozygous deletion in these immortalized clones can be estimated as at least 37 --42 Kb based on the published size of the genomic CDKN2A/B locus in the rat and the mouse. The lack of published Syrian hamster DNA sequence in the vicinity of CDKN2A/B precluded further delineation of the deleted regions. However, our previous detailed cytogenetic analysis of X-ray-immortalized SHD clones 8 had revealed a predominantly diploid karyotype with no evidence of non-random gross chromosome alterations at the level of G-banding. p53 point mutations in B(a)P/BPDE-and MNUA-immortalized clones The tumour-suppressor gene p53 is frequently mutated in many types of human cancer, with the majority (ca 75%) categorized as missense mutations. 18 In recent studies by others, 19, 20 p53 has also been strongly implicated in the high-frequency spontaneous immortalization (senescence bypass) of cultured transgenic mouse embryo fibroblasts expressing a humanized p53 gene (see Discussion). In the Syrian hamster, several studies have found mutations in p53 in chemically induced pancreatic ductal adenocarcinomas, 21, 22 buccal pouch adenocarcinomas 23 --25 and lung tumours. 26 The p53 cDNA of the Syrian hamster has been sequenced by others 27 and was later localized to hamster chromosome 9 by in situ hybridization. 28 Here, we performed direct mutational analysis by PCR amplification of exons 2 --9 (corresponding to at least 1000 bp of the coding region) of p53 incorporating the proline-rich domain and DNA-binding domain (DBD). Dideoxy sequencing of PCR products was carried out using three sets of optimized primers (see Supplementary Table S1 ). Table 3a summarizes the p53 mutations found in our 25 carcinogen-immortalized SHD clones; the p53 and Mdm2 mRNA expression levels are shown in Supplementary Figure S1 . Missense mutations were detected in six of eight B(a)P/BPDE-induced clones and three of five MNUAinduced clones (Tables 2 and 3 ). In contrast, no p53 mutations were found in replicate untreated mass SHD cultures, or in SHD clones immortalized by IR, DMS or NiCl 2 , indicating a distinct preference of the two powerful point mutagens in targeting p53. Furthermore, the p53 mutations found were largely consistent with the known mode of action of the carcinogens used to immortalize the cells. For example, all of our B(a)P/BPDEassociated p53 mutations were base transversions (G to T, G to C or A to C), whereas two of the three p53 mutations associated with the O 6 -guanine methylating agent MNUA were G to A transitions. All of the observed p53 mutations were in the DBD of the gene. By determining the codon alignment of hamster with human p53, five of the mutations could be categorized as being located at the equivalent of base-pair 'hot spots' associated with various common human cancers (lung, liver, breast) (Sanger, COSMIC and IARC databases: http://www.sanger.ac.uk; http://www.sanger.ac.uk/genetics/CGP/cosmic/ and http://p53.iarc.fr/ index.html); two of these have been associated with local conformational distortions at human equivalent codons (HE) Carcinogen-specific events driving senescence bypass H Yasaei et al 
Abbreviations: B(a)P, benzo(a)pyrene; BPDE, benzo(a)pyrene-anti-diol epoxide; MNUA, N-methyl-N-nitrosourea; Mut, mutant; SHD, Syrian hamster dermal; WT, wild type. A detailed summary of point mutations observed in p53 (a) and p16 (b) genes. Hamster and equivalent human codon numbers are shown, as well as wild-type and mutant codons for comparison. Carcinogen-specific events driving senescence bypass H Yasaei et al R249S and G245S. One B(a)P clone contained two p53 DBD mutations at HE codons 273 (human 'hot spot') and 218 (uncommon in human cancer---see Table 3a for actual hamster codons targeted). B(a)P/BPDE-induced mutations result from N 2 -guanine and, less commonly, N 6 -adenine diol epoxide adducts, 29 and our results are consistent with this.
p16 point mutations in B(a)P-and MNUA-immortalized clones In human cancers, p16 point mutations are less common than in p53 but they are still encountered in B15% of human tumours (COSMIC database). Point mutational alterations of p16 have been documented in chemically induced Syrian hamster tumours including pancreatic 30 and cheek pouch tumours. 31 The Syrian hamster p16 gene 32, 33 and its upstream promoter region 34 have been sequenced. Sequencing p16 cDNA prepared from our immortalized clones revealed point mutations in two clones (Table 3b) ; that is, in one (5MNU4) that bypassed senescence after MNUA treatment (C to T transition), and the other (BP1.3) following B(a)P exposure (G to C transversion), targeting hamster codons 92 and 62, respectively. It is noteworthy that mutations in each of these two regions of p16 have been associated with chemically induced hamster pancreatic tumours and shown by nuclear magnetic resonance spectroscopy to cause significant perturbation of the global p16 protein structure. 30 The p16 mutation in BP1.3 was accompanied by loss of the other p16 allele, whereas that in 5MNU4 carried a p53 DBD mutation at hamster codon 155.
Epimutational silencing of p16 expression associated with senescence bypass induced by nickel, a non-genotoxic human carcinogen We were next interested in establishing molecular events underlying immortalization induced by a non-genotoxic human carcinogen. Nickel compounds are well-established human occupational carcinogens, strongly associated with human lung and nasal cancers. Epigenetic mechanisms (both DNA hypermethylation and histone modifications) have been implicated in the carcinogenicity of nickel. 15 Our previous work indicates that soluble nickel (NiCl 2 ) is an extremely efficient immortalizing agent in the SHD system. 8 In the present study, analysis of p16 mRNA in four nickel-immortalized SHD clones revealed markedly reduced expression in all clones compared with mRNA levels in untreated early-passage SHD cells; in two immortalized lines, 5NL3 and 6NL2, mRNA levels were virtually undetectable (Figure 1a) . CNV analysis indicated loss of one allele of p16 and ARF in three independently induced lines (5NL3, 6NL2 and 6NL9; Table 2 ). In order to determine the mechanism of transcriptional downregulation of the remaining p16 allele associated with nickel-induced SIPS bypass, we treated three nickel-immortalized clones (5NL3, 6NL2 and 5NH2), with the demethylating agent 5 0 -aza-2 0 -deoxycytidine (5-aza-dC) for 24 and 48 h and measured changes in p16 mRNA expression. We observed (Figure 2a ) dose-dependent increases in p16 expression in all three clones, suggesting that DNA hypermethylation induced by nickel exposure, most often accompanied by loss of one allele of p16, underlies SIPS bypass and immortalization induced by nickel ions.
We performed the same analysis on one B(a)P-induced (BP1.2) and one MNUA-induced (5MNU22) immortalized SHD line that showed reduction in p16 expression in the initial analysis (Figure 1a ). In the case of clone BP1.2, 48 h treatment with 5--aza-dC resulted in partial reinstatement of p16 mRNA; 5 MNU22 did not respond but in this analysis showed only a marginal base-line reduction in p16 expression compared with control SHD cells (Figure 2a) .
To investigate the methylation status of the p16 promoter, we next bisulphite-converted genomic DNA from seven immortalized samples (four nickel induced, one B(a)P induced and one MNUA induced; Figure 2b ). Following conversion, each genomic DNA sample was cloned and 300 nucleotide base-pairs upstream of p16 exon-1 sequenced. No methylation was found in primary SHD or 5MNU22 clones (Figure 2b, open symbols) . However, in the remaining five clones (one B(a)P and four nickel induced) hypermethylation of the p16 promoter was clearly evident (Figure 2b, closed symbols) . Out of the 21 possible CpG sites spread across two cluster regions, the smaller CpG cluster (immediately upstream of p16 exon-1) was heavily methylated in all five clones. The degree of hypermethylation varied from 6/21 CpG sites in BP1.2 to 16/21 CpG sites in 5NL3. These data strongly suggest that the highly targeted p16-promoter DNA methylation immediately upstream of exon-1 is responsible for epimutational silencing of p16, and for consequent SIPS/OIS bypass.
Overexpression of p16/ARF in senescence bypass induced by B(a)P/BPDE, and identification of expression alterations in p15(INK4B) as a possible event cooperating with heterozygous p53 mutations in immortalization One common feature of the carcinogen-immortalized cell lines analyzed in this study was pronounced overexpression of p16 and/or ARF in many of the clones that had not sustained double CDKN2A/B allele losses (Figures 1a and b) . This was particularly evident in 7/8 lines immortalized by B(a)P or BPDE, including those (6/8) that had carcinogen-induced p53 mutations. The only exception was clone BP1.2, which had epigenetically silenced p16 (see above) and sustained a single p16 allele loss (but showed increased levels of ARF expression). It was at first sight perplexing to note that four of the BPDE/B(a)P-immortalized lines (BP1.1, BP1.3, 5BP1 and 5BP2) overexpressed p16/ARF, despite at the same time sustaining p16, p15 and ARF single allele losses (Table 2) . However, one appealing explanation for how these losses could confer a selective advantage became apparent after examining expression levels of p15. In three of the lines (BP1.1, 5BP1 and 5BP2) p15 expression was silenced or severely reduced, thus raising the novel possibility that p15 transcriptional repression may cooperate with a single-point mutation in the DBD of p53 in senescence bypass. The fact that immortalization of SHD cells by B(a)P, BPDE and MNUA (unlike that induced by IR and nickel ions) commonly appears in our cultures as a clearcut twostage process (see Trott et al. 8 and Discussion below) is consistent with this hypothesis.
Overexpression of p16/ARF was again a feature of SIPS/OIS bypass induced by the simple monofunctional alkylating carcinogen MNUA; 4/5 lines showed substantial overexpression (Figures 1a  and b) . Two of the clones (5MNU22 and 5MNU31) had, as with B(a)P/BPDE, also sustained p16/ARF allele losses, raising the question of the significance of the latter in the (again, two-stage) immortalization process. However, in contrast to the B(a)P/BPDE clones, there was no evidence of p15 silencing in these two immortal clones (and no p53 point mutations were detected in them). The remaining three MNUA-immortalized lines (5MNU4, 5MNU33 and 5MNU35) carried single heterozygous p53 mutations but retained both p16/ARF alleles. 5MNU4 also possessed a point mutation in p16 (that may be functionally disabling---see above, Li et al. 30 and Table 3 ). Of possible significance to the mechanism of SIPS/OIS bypass in these cases, clones 5MNU22 and 5MNU35 displayed markedly reduced levels (by 70--80%) of Rb1 mRNA compared with the parent SHD cells (Figure 1d) ; Rb1 expression was also reduced to below 50% of control levels in 4/6 B(a)P-induced clones. Such qualitative changes in Rb1 expression may therefore contribute to SIPS bypass, but this requires further investigation. In this connection, we were unfortunately unable to examine the Rb1 gene for point mutations because of the lack of availability of the complete cDNA sequence for Syrian hamster Rb1. We are currently sequencing the full-length hamster Rb1 cDNA and cis-acting upstream promoter region to correct this deficiency.
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DISCUSSION
In this study, we used a panel of chemical and physical carcinogens with widely diverse modes of action (Table 1) to probe the mechanisms of induced senescence (SIPS/OIS) bypass in cultures of early-passage SHD cells. The extremely low rate of spontaneous immortalization of SHD cells 8, 9 facilitated this approach. Because of the well-documented importance of the p16 --Rb and ARF --p53 --p21 antiproliferative pathways in mediating cellular senescence (reviewed in Newbold, 1 Sikora et al., 2 Ruas and Peters 16 and Goh et al. 18 ), we examined genetic alterations in p16 and p53 in SHD clones immortalized by our panel of carcinogens. With ionizing radiation (both high-LET fast neutrons and low-LET X-rays), p16 double allele losses were universally observed. These deletions also invariably included the p15 (CDKN2B/INK4B) gene but were not accompanied by mutations or CNVs in p53. The sole DMS-induced clone also carried a and therefore served as a useful control to eliminate non-p16-specific 5 --aza-dC effects on cell proliferation. Primary SHD cells senesced as expected after reaching passages 5 --6, accompanied by elevated p16 expression. Dimethylsulphoxide (DMSO) controls were included in all experiments. It should be noted that the levels of p16 mRNA following 48-h treatment of 5NL3 cells with 5 --aza-dC, in the experiment shown in (a), were 227-fold those in the 5NL3 DMSO-treated control, but were increased by only 25-fold (2 days) in the experiment depicted in (c). This was probably because of barely detectable control p16 mRNA levels in the former experiment, which was performed on earlier passage cells. In (c) the majority of 5 --aza-dC-treated 5NL3 cells (48 h) entered senescence within 96 h, whereas 5 --aza-dC-treated 4XH11 cells remained immortal.
complete deletion of CDKN2A/B. With reference to previous studies of the role of p16 in mediating SIPS/OIS bypass in both mouse embryo fibroblast 5 and human epithelial cell culture 35 models, we are confident that this complete loss of function of the whole CDKN2A/B locus is sufficient to explain immortalization (senescence bypass) by these agents. Alterations associated with immortalization induced by the powerful chemical carcinogens and point mutagens B(a)P, BPDE and MNUA were more complex. Most (70%) immortalized clones carried a single (heterozygous) p53 mutation (Table 2) ; one clone had two p53 mutations, possibly in different alleles, whereas a second carried both p53 and p16 point mutations, and a third a single p16 point mutation. Additionally, qPCR-based CNV studies showed loss of a single p16 (and p15) allele in all except one B(a)P/ BPDE-induced clone and in 40% of MNUA-immortalized clones. As indicated above, all p53 point mutations were in the region encoding the p53 DBD and the majority were in the hamster equivalent of mutational hot spots found in human cancers; the point mutational signature was largely consistent with the known mode of action of the carcinogen used. As described, each of the two p16 point mutations were in regions previously associated with chemically induced Syrian hamster carcinomas.
Genetic alterations in clones in which senescence bypass had been induced by the non-genotoxic human carcinogen nickel were restricted to a single allele loss of p16 in 75% of clones immortalized by this agent. Significantly, all clones showed extinguished expression of p16 (in 50% of the clones p16 mRNA was virtually undetectable). Evidence of epigenetic restoration of p16 expression was observed after treatment of the cells with 5 --aza-dC. It is notable that clone 5NL3, in which p16 mRNA returned to levels seen by us in senescing normal SHD cells, rapidly underwent typical senescence 96 h after treatment (see Figure 2c and Yaswen and Stampfer 36 ). In these cultures, subclones of immortal cells reappeared on the senescent background that had retained, or alternatively regained, complete p16 silencing (Figure 2c ) and these rapidly dominated the cultures. The fact that we observed, in several independently immortalized SHD lines (BP1.2 and all four lines immortalized by nickel), silencing of p16 expression in the presence of increased levels of ARF mRNA led us to conclude that, in the Syrian hamster, p16 is the critical target for SIPS/OIS bypass rather than ARF as in mouse cells. 37 Perhaps surprisingly, the Syrian hamster appears to resemble humans more closely than mouse in this respect (as in resistance to spontaneous SIPS/OIS bypass) and may indicate that Syrian hamster cell transformation systems are more representative models for human cells with regard to this rate-limiting event in overcoming senescence.
The alterations in p16 and p53 underlying SIPS/OIS bypass described above provide an attractive explanation for our previous observations that immortalization of SHD cells occurs via either a single-step process (which we named Type 1 immortalization) or a two-step process (Type 2) and that this is highly carcinogen specific (see Trott et al. 8 and Newbold et al. 9 and Supplementary  Table S2 ). Thus, both forms of IR as well as DMS induce exclusively Type 1 immortalization; that is, characterized by rare (ca 10 À6 /cell treated) immortal clones that always appear against a background of senescent cells and proliferate continuously thereafter without signs of population senescence. In complete contrast, the powerful point mutagens B(a)P and MNUA induce predominantly (490%) Type 2 immortalization 8 in which two clearcut stages are evident before complete senescence bypass and immortalization are achieved. With Type 2 kinetics, rare clones of cells initially appear with extended population lifespan, but which generate large numbers of terminally senescent cells and struggle to expand until a second abrupt event leads to overgrowth of a variant that resembles a Type 1 clone. 8 The present molecular characterization of carcinogen-immortalized clones shows that Type 1 immortalization targets p16 and, in the case of induction by IR, is accompanied in every case by complete deletion of both alleles of the whole CDKN2A/B locus (p16, ARF and p15). From the observed kinetics of immortalization (see above), these events appear to occur in a single step following a short exposure to both high-and low-LET IR. Simultaneous biallelic deletion of CDKN2A/B after a brief pulse of radiation is difficult to explain based on current knowledge (that is, assuming IR-generated double-strand breaks, the most deleterious lesion induced by IR, and their repair, are the source of such deletions). 38 Indeed, our results may point to a novel, highly efficient mechanism by which IR (and possibly other clastogenic but weakly point mutagenic carcinogens, such as DMS) can eliminate the function of this critical human tumoursuppressor gene. Homozygous deletions involving p16/ARF (CDKN2A) and p15 (CDKN2B) are common in some human cancers (for example, bladder carcinoma) 39 and have been associated with adverse prognosis (for example, in malignant melanoma). 40 Efficient inactivation of three proteins with tumour-suppressive properties could be one reason why the CDKN2A/B locus appears subject to an unusually high frequency of deletions. 41 In addition, it has been proposed that certain structural features of the relevant chromosomal region contribute to its fragility (for example, proximity to LINE repeats) in human cells 39 and, interestingly, that different mechanisms of homozygous deletion (including non-homologous end-joining and less well-characterized variant mechanisms) predominate in different types of cancer. 42, 43 If confirmed in human cell transformation models (for example, in 'stasis' bypass in normal early-passage human mammary epithelial cells), 44 our results using the SHD system may well have important implications for understanding the mechanisms of human radiation carcinogenesis, and risks inherent in IR exposure.
A key question that requires resolution is whether there are additional events that cooperate with a single heterozygous p53 mutation in Type 2 (two-stage) immortalization and to what extent these reflect what happens in human cancers. In two recent comprehensive studies of events underlying spontaneous 19, 20 and benzo(a)pyrene-induced 45 immortalization of transgenic (biallelic) p53-humanized mouse embryo fibroblasts, it was proposed that single heterozygous p53 DBD mutations may be haploinsufficient, possibly collaborating with other 'modest' alterations in expression of elements of cell growth regulatory pathways to induce full immortalization. Gain-of-function p53 mutations and dominantnegative alterations may be responsible for a small proportion of immortalizing events.
Our present study may offer additional clues to this question. The striking two-step kinetics of induced SIPS/OIS bypass by powerful point mutagenic carcinogens, in the absence of spontaneous immortalization, suggests that a single carcinogenspecific p53 point mutation located in a variety of positions in the DBD-encoding region of hamster p53 commonly leads to an imperfectly senescence-bypassed (Type 2, Stage 1) clone, indicating p53 haploinsufficiency for this intermediate phenotype. The second clearcut event leading to full immortalization (Stage 2) occurs after at least 20 population doublings of the Stage 1 clone. 8 In a search for possible molecular events responsible for the second step, we first noted that Rb levels were reduced to 20 --50% of those in control cells in two B(a)P/BPDE-and four MNUAinduced clones, which may be causally significant in senescence bypass induced by these carcinogens. Furthermore, a detailed examination of the expression and CNVs of genes from the CDKN2A/B locus in the fully immortalized cells derived from our study revealed loss of a single copy of p16 and p15 in the majority of B(a)P/BPDE-induced clones. However, expression levels of p16 mRNA, far from being reduced, were in fact markedly increased compared with those measured in normal SHD cell controls (possibly in response to the partial senescence bypass following p53 point mutation). However, when p15 expression levels were examined in B(a)P/BPDE-immortalized cells, half of the clones analyzed displayed undetectable or barely detectable levels of p15 mRNA. Thus, p15 loss of expression should be considered a candidate event cooperating with a p53 heterozygous DBD mutation in B(a)P-induced two-step immortalization.
With regard to the function of p15 as a tumour suppressor linked to SIPS/OIS, it is known that there exists a strong effect of codeletion of p15 and p16 on tumour susceptibility in genetically manipulated 'knockout' mice, 46 and that p15 is a critical tumour suppressor in the absence of p16 (perhaps fulfilling a backup role). Furthermore, it has recently been proposed that p15 acts as a cellular stress sensor (reviewed in Peters 47 ) and has been identified as a marker for OIS in unbiased screens. 7 Finally, short hairpin RNAmediated knockdown of the p15 negative regulator Jhdm1b (an H3K36 demethylase) results in senescence in primary mouse embryo fibroblasts. 48 It is also noteworthy that all immortalized cell clones induced by IR, which had physically lost both copies of p16 and p15, exhibit by far the most completely immortalized phenotypes that we have seen in the SHD system. 8 Such clones generate far fewer senescent cells within mass cultures than, for example, nickel-immortalized lines, which display epigenetically silenced p16 transcription in the presence of normal or supra-normal levels of p15 expression. We are currently using small interfering RNA and short hairpin RNA 'knockdown' approaches, targeting p16 and/or p15, in both primary SHD and human epithelial cells, as well as SHD clones carrying only a single p53 point mutation, to test more rigorously this intriguing hypothesis.
MATERIALS AND METHODS

Cell culture
Primary dermal fibroblasts of Syrian hamster (Mesocricetus auratus; SHD cells) were prepared from newborn skins exactly as described previously. 8 SHD cells were grown at 37 1C (10% CO 2 ) in Dulbecco's modified Eagle's medium (Sigma-Aldrich, St Louis, MO, USA) supplemented with 15% fetal calf serum and 1% GlutaMAX (Invitrogen, Life Technologies, Carlsbad, CA, USA). Cells were confirmed as mycoplasma free using established PCRbased methods 8 and, for immortalization assays, were subcultured at a ratio of 1:3 or 1:5 (depending on the rate of cell growth) every 3 --4 days.
Generating immortal SHD clones
Aliquots of 10 7 exponentially dividing SHD cells were irradiated in suspension with X-rays, g-rays or fast neutrons, or treated as exponentially dividing monolayers with chemical carcinogens, as previously described. 8, 9 Postmitotic cultures were maintained for at least 4 weeks before being pronounced senescent, and induced cell clones that outgrew their normal counterparts were maintained in exponential culture for at least 50 population doublings before being scored as immortal.
Isolation of nucleic acids
Total RNA was extracted from pre-senescent and senescent SHD cells, and carcinogen-immortalized clones, in a nuclease free environment, using either TRIzol (Invitrogen) or RNeasy Plus Mini Kit (Qiagen, Venlo, Netherlands) following the manufacturers' guidelines. RNA quantity and quality were determined using Nanodrop 2000c (Invitrogen) spectrophotometry and samples then stored at À80 1C before further analysis. Genomic DNA was isolated using a Wizard genomic DNA purification kit (Promega, Madison, WI, USA) and stored at À20 1C.
Gene expression analysis using quantitative real-time PCR Gene expression analyses were performed using cDNA made from 1 mg of total RNA using Superscript III (Invitrogen) reverse transcription enzyme and 250 ng of random hexamers (Invitrogen). Relative quantification of synthesized cDNAs was performed on a 7900HT Fast Real-Time PCR System (Applied Biosystems) using their SYBR Green assay. The primer sets for each gene were designed using the publicly available nucleotide sequence (NCBI database) with the aid of Primer Express 2.0 software (Applied Biosystems). Each primer set was optimized empirically for annealing temperature and concentration using a standard PCR technique (1.1 Â concentration of ReddyMix Mastermix (ABgene, Thermo Scientific, Waltham, MA, USA) containing 1.5 mM of MgCl 2 ). The primer sequence of all genes used in gene expression analysis is shown in Supplementary Table S1. CNV analysis Copy number analysis of genes was performed using a commercially available customized TaqMan copy number assay (Applied Biosystems) to detect CNV in carcinogen-immortalized SHD clones. Determinations (four replicates) were performed in an ABI 7900HT qPCR machine (Applied Biosystems) on 20 ng of samples of genomic DNA, each repeated at least three times for consistency and reproducibility. The 2 ÀDDCt values were calculated using SDS v2.3 and CopyCaller v1.0 software (Applied Biosystems) as published. 49 The sequences of all custom-made copy number assay primers, probes of genes of interest and reference genes are shown in Supplementary Table S1 .
Mutation screening of p53 and p16/ARF The PCR products of p16 exon 1a and exon 2 were sequenced after purification (QIAquick PCR Purification Kit, Qiagen). Each cDNA sample was sequenced using a Beckman Coulter CEQ 8000 analyser (Brea, CA, USA) (100 ng of cDNA was processed with a dye terminator cycle sequencing, Quick Start kit). Each forward and reverse primer of p16 exon 1a and exon 2 was sequenced separately. Three primer sets were designed spanning exons 2 to 9 of the Syrian hamster p53 gene (see Supplementary Table S1 ). cDNAs from each primer set were purified as described above (100 ng of each cDNA sequenced). Sequence alignments were carried out using the CLC Main Workbench software v5.5 (CLCbio, Aarhus, Denmark) made available on limited licence from the CLCbio website. Forward and reverse alignments from immortal SHD clones were compared with primary Syrian hamster (M. auratus) sequences and the published reference p53 nucleotide sequence (GenBank: U07182.1). A synonymous p53 base substitution (G to A in codon 333) was observed in all presenescent and immortalized SHD clones that reflected a strain variant or single-nucleotide polymorphism (data not shown).
5
0 -Aza-2 0 -deoxycytidine treatment and bisulphite sequencing Four nickel-induced immortal clones were treated with 5 mM 5 --aza-dC (Sigma) (two treatments with a 4-h interval) and total RNA extracted 24 and 48 h later. Dimethylsulphoxide-treated cells were included as a control. The relative expression of p16 was measured using real-time qPCR as described above. Bisulphite conversion was performed after processing 1 mg of genomic DNA with a MethylCode bisulphite conversion kit (Invitrogen). The p16 promoter regions were analysed for cytosine methylation using the primer set shown in Supplementary Table S1 . Bisulphite sequencing was performed after converted genomic DNAs were cloned using a TOPO TA cloning kit (Invitrogen); a minimum of 10 clones were picked for sequence analysis. Sequencing was carried out using specific bisulphite sequencing primers designed using MethPrimer. 50 (Supplementary Table S1 ).
